000 | 07181cam a2201021 i 4500 | ||
---|---|---|---|
001 | ocn868511726 | ||
003 | OCoLC | ||
005 | 20171224114524.0 | ||
006 | m o d | ||
007 | cr ||||||||||| | ||
008 | 140117s2014 enk ob 001 0 eng | ||
010 | _a 2014002242 | ||
040 |
_aDLC _beng _erda _epn _cDLC _dYDX _dMHW _dN$T _dDG1 _dCUS _dUKMGB _dYDXCP _dOCLCF _dNLGGC _dE7B _dCDX _dEBLCP _dDEBSZ _dCOO _dOCLCQ _dOCLCO _dLOA _dDG1 |
||
016 | 7 |
_a016697425 _2Uk |
|
019 |
_a875820397 _a878148990 _a960202546 _a961516735 _a962726974 |
||
020 |
_a9781118820148 _q(ePub) |
||
020 |
_a1118820142 _q(ePub) |
||
020 |
_a9781118820179 _q(Adobe PDF) |
||
020 |
_a1118820177 _q(Adobe PDF) |
||
020 |
_a9781118820186 _q(electronic bk.) |
||
020 |
_a1118820185 _q(electronic bk.) |
||
020 | _a0470671041 | ||
020 | _a9780470671047 | ||
020 |
_z9780470671047 _q(cloth) |
||
029 | 1 |
_aDEBSZ _b431662967 |
|
029 | 1 |
_aGBVCP _b813902444 |
|
029 | 1 |
_aNZ1 _b15624996 |
|
029 | 1 |
_aNZ1 _b15920442 |
|
029 | 1 |
_aAU@ _b000052429159 |
|
035 |
_a(OCoLC)868511726 _z(OCoLC)875820397 _z(OCoLC)878148990 _z(OCoLC)960202546 _z(OCoLC)961516735 _z(OCoLC)962726974 |
||
042 | _apcc | ||
050 | 0 | 0 | _aRM302.5 |
060 | 1 | 0 | _aQV 771 |
072 | 7 |
_aBUS _x032000 _2bisacsh |
|
072 | 7 |
_aSOC _x000000 _2bisacsh |
|
082 | 0 | 0 |
_a363.19/463 _223 |
049 | _aMAIN | ||
130 | 0 | _aPharmacovigliance. | |
245 | 1 | 0 |
_aMann's pharmacovigilance / _cedited by Elizabeth B. Andrews, Nicholas Moore. |
250 | _aThird edition. | ||
264 | 1 |
_aChichester, West Sussex, UK ; _aHoboken, NJ : _bWiley Blackwell, _c2014. |
|
300 | _a1 online resource. | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
500 | _aPreceded by Pharmacovigilance / editors, Ronald D. Mann, Elizabeth B. Andrews. 2nd ed. c2007. | ||
504 | _aIncludes bibliographical references and index. | ||
588 | 0 | _aPrint version record and CIP data provided by publisher. | |
520 | _aMann's Pharmacovigilance is the definitive reference for the science of detection, assessment, understanding and prevention of the adverse effects of medicines, including vaccines and biologics. Pharmacovigilance is increasingly important in improving drug safety for patients and reducing risk within the practice of pharmaceutical medicine. This new third edition covers the regulatory basis and the practice of pharmacovigilance and spontaneous adverse event reporting throughout the world. | ||
505 | 0 | _aCover; Title page; Copyright page; Contents; Contributors; Foreword; 1: Introduction: Updated from Second Edition; Background; Diagnosing Adverse Drug Reactions; Current Methods of Pharmacovigilance; Hypothesis-Generating Methods; Spontaneous Adverse Drug Reaction Reporting; Prescription-Event Monitoring; Other Hypothesis-Generating Methods; Hypothesis-Testing Methods; Conclusion; References; 2: History of Pharmacovigilance; Early History of Drug Safety; Recent History; Pre-1962; Turning Point: The Federal Food, Drug and Cosmetics Act; Gradual Increase in Regulatory Authority. | |
505 | 8 | _aTectonic Shift: ThalidomidePost-Thalidomide Evolution of Regulation; United States of America; United Kingdom; Germany; Scandinavia; Japan; World Health Organization; France; Special Issues in Pharmacovigilance; Examples of Drugs that were Withdrawn from the Market; Bendectin; Thalidomide: Today's Approved Uses; Pharmacovigilance is Not Just for Regulators; References; Part I: The Regulatory Basis of Pharmacovigilance; 3: Legal Basis: European Union; Introduction; Reorganization of the European Union Regulatory System. | |
505 | 8 | _aObligations of being a Marketing Authorization Holder and being Granted a Marketing AuthorizationSignal Detection and Risk Management; Reporting Requirements; Transparency and Communication; Pharmacovigilance Enforcement; Further Information about Proposed New Legislation and Guidelines; 4: Ethical Oversight, Consent, and Confidentiality; Introduction; Practical Implications of Ethical Oversight; The Privacy and Security of Health Data; The Linkage of Electronic Health Data; The Conduct of Scientifically Sound Studies; Ethical Oversight and Privacy Law and Resulting Dilemmas; The Common Rule. | |
505 | 8 | _aState LawsThe Health Insurance Portability and Accountability Act; Dilemmas Arising from the Health Insurance Portability and Accountability Act; Directions for Future Ethical Oversight and Privacy Provisions; References; 5: Pharmacovigilance-Related Topics at the Level of the International Conference on Harmonisation1; Introduction; The International Conference on Harmonisation Step Process; ICH Step 1: Development of Draft Consensus ICH Guideline or Recommendations; ICH Step 2: Confirmation of Six Party Consensus; ICH Step 3: Regulatory Consultation. | |
505 | 8 | _aICH Step 4: Adoption of Tripartite ICH Guideline or RecommendationsICH Step 5: Implementation of ICH Guideline or Recommendations; Pharmacovigilance-Related International Conference on Harmonisation Topics; Topic ICH-E2A: Clinical Safety Data Management -- Definitions and Standards for Expedited Reporting; ICH-E2D Topic: Post-Approval Safety Management -- Definitions and Standards for Expedited Reporting; ICH-E2B Topic: Clinical Safety Data Management -- Data Elements for Transmission of Individual Case Safety Reports. | |
505 | 8 | _aICH-E2C Topic: Clinical Safety Data Management -- Periodic Benefit-Risk Evaluation Report (PBRER). | |
650 | 0 | _aPharmacovigilance. | |
650 | 0 |
_aDrug-Related Side Effects and Adverse Reactions _vclassification. |
|
650 | 0 | _aInternationality. | |
650 | 0 |
_aPharmacoepidemiology _vMethods. |
|
650 | 0 | _aProduct Surveillance, Postmarketing. | |
650 | 2 | _aPharmacovigilance. | |
650 | 2 |
_aDrug-Related Side Effects and Adverse Reactions _xclassification. |
|
650 | 2 | _aInternationality. | |
650 | 2 |
_aPharmacoepidemiology _xmethods. |
|
650 | 2 | _aProduct Surveillance, Postmarketing. | |
650 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xclassification. |
|
650 | 4 | _aInternationality. | |
650 | 4 |
_aPharmacoepidemiology _xmethods. |
|
650 | 4 | _aPharmacovigilance. | |
650 | 4 | _aProduct Surveillance, Postmarketing. | |
650 | 7 |
_aBUSINESS & ECONOMICS _xInfrastructure. _2bisacsh |
|
650 | 7 |
_aSOCIAL SCIENCE _xGeneral. _2bisacsh |
|
650 | 7 |
_aPharmacoepidemiology. _2fast _0(OCoLC)fst01060242 |
|
655 | 4 | _aElectronic books. | |
655 | 0 | _aElectronic books. | |
700 | 1 |
_aAndrews, Elizabeth B., _eeditor. |
|
700 | 1 |
_aMoore, Nicholas, _eeditor. |
|
776 | 0 | 8 |
_iPrint version: _bThird edition. _dChichester, West Sussex, UK : John Wiley & Sons Inc., 2014 _z9780470671047 _w(DLC) 2014000062 |
856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118820186 _zWiley Online Library |
938 |
_aCoutts Information Services _bCOUT _n28112612 |
||
938 |
_aEBL - Ebook Library _bEBLB _nEBL1662669 |
||
938 |
_aebrary _bEBRY _nebr10856801 |
||
938 |
_aEBSCOhost _bEBSC _n752698 |
||
938 |
_aYBP Library Services _bYANK _n11072743 |
||
938 |
_aYBP Library Services _bYANK _n11744590 |
||
938 |
_aYBP Library Services _bYANK _n11751003 |
||
994 |
_a92 _bDG1 |
||
999 |
_c13234 _d13234 |